Entrada Therapeutics, Inc. 8-K

What Happened

• Entrada Therapeutics, Inc. announced its financial results for the quarter ended March 31, 2026 and disclosed positive topline results from Cohort 1 of participants with Duchenne muscular dystrophy treated with ENTR-601-44 in the Phase 1/2 ELEVATE-44-201 study. The company furnished the financial-results press release and the clinical topline press release as exhibits to its Current Report on Form 8-K filed May 7, 2026.

Key Details

• Filing date: May 7, 2026 (Form 8-K covering Items 2.02 and 7.01).
• Quarter covered: Quarter ended March 31, 2026 (financial results announced).
• Clinical update: Positive topline results reported for Cohort 1 in the Phase 1/2 ELEVATE-44-201 study of ENTR-601-44 for Duchenne muscular dystrophy.
• Press releases were furnished as exhibits to the 8-K (press release for financial results and separate press release for the clinical topline).

Why It Matters

• The company provided both a routine quarterly financial update and an important clinical development update. Positive topline data from an early cohort in a Phase 1/2 trial is a development milestone that may affect the program’s next steps, regulatory planning, and investor interest. The financial-results disclosure gives investors a timely look at the company’s recent operating performance; see the furnished press releases for the specific financial figures and detailed clinical data.